Bubendorf, Switzerland, Friday, August 30, 2018 – CIS Pharma announces the approval of a vial adaptor specific for the preparation and injection of intracameral cefuroxime. Consequently, the adaptor was produced and is expected to reach the market shortly. The development is innovative device that prevents the 10mg/ml cefuroxime sodium solution from particulate contamination, containing several 5-micron filters. After reconstitution of the cefuroxime powder, the vial adaptor separates into two parts, immediately offering the surgeon an injection syringe with his cannula of choice. The second part of the adaptor closes the cefuroxime vial and prevents multi-use of the overfill contained. West is a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines.

About CIS Pharma’s cefuroxime application system

The cefuroxime application system is CIS Pharma’s patented drug/device combination for preparation and injection of cefuroxime intracameral antibiotic to prevent Endophthalmitis after cataract surgery. It meets the cataract surgeon’s need to dilute and inject 1mg cefuroxime in a safe, precise and standardized manner. Every year, 20 million cataract patients receive an intraocular lens. Endophthalmitis, also called intravitreal infection, is a rare but severe inflammatory condition of the eye, caused by microbial contamination during the surgical procedure. Cefuroxime intracameral prophylaxis was found to reduce the risk of Endophthalmitis by a factor 5, whereas topical antibiotics have no effect on the outcome.

About CIS Pharma AG

CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of therapeutics that are the standard of care, thereby improving patient’s experience and treatment outcome. Medical need, patient centricity and digital technology are key to our research and development programs. CIS Pharma is located in the region of Basel, Switzerland, one of the most successful life sciences locations in the world. For more information about the company, visit our website www.cis-pharma.com.